Drug Profile
MDV 4463
Alternative Names: MDV4463Latest Information Update: 28 Mar 2019
Price :
$50
*
At a glance
- Originator Medivation
- Class Small molecules
- Mechanism of Action Sterol regulatory element binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Mar 2019 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in USA
- 28 Sep 2016 Medivation has been acquired by Pfizer
- 26 Feb 2016 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (unspecified route)